Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Potential alternative treatment for corneal infections discovered

Fight for Sight-funded research identifies alternative treatment to antibiotics

Dr Darren Ting
A researcher at the University of Nottingham has identified a potential new treatment for corneal infections that can cause sight loss.

Dr Darren Ting’s (pictured) Fight for Sight-funded research explored the use of antimicrobial peptide drugs, during which he discovered the possible alternative treatment to antibiotics.

For the study, Dr Ting created a number of new artificial peptides, demonstrating how they could kill bacteria grown in laboratory dishes effectively, and faster than antibiotics.

While the initial findings are promising, more work needs to be performed to develop the modules into drugs that can be used in the clinic. Consequently, Dr Ting is about to embark on further research that has been funded by Fight for Sight and the Medical Research Council.

It is estimated that almost two million people a year develop a sight-threatening corneal infection. They will often require antibiotic treatment in hospital to get the infection under control.

Speaking about the findings, Dr Ting said: “We hope to one day bring this compound into the clinic as an easy to apply treatment for patients with corneal infections. An attractive characteristic of this class of antimicrobials is that they are broad-spectrum, meaning if they work on bacteria, we may be able to modify them to be able to treat other types of infection in the future.”

Dr Ting’s initial research was funded by the Fight for Sight Primer Fellowship Award and performed under the supervision of Professor Harminder Dua and Dr Imran Mohammed.

Advertisement